SLC16A3 and ovarian cancer: Higher expression of SLC16A3 or MCT4 (HR or Hazard Ratio 1.37) was found to be significantly (p = 0.021) associated with poor Overall Survival (OS) in Ovarian cancer patients (Figure 4a), although no significant contribution was observed for Recurrence-Free Survival (RFS) (Figure 4b).